Tirzepatide
- Generic Name
- Tirzepatide
- Brand Names
- Mounjaro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2023788-19-2
- Unique Ingredient Identifier
- OYN3CCI6QE
- Background
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclini...
- Indication
Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In Europe, it may be used as monotherapy or in combination with other drugs used to treat diabetes.
...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Tirzepatide for Meth Use Disorder
- Conditions
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT06745128
Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants
- First Posted Date
- 2024-12-17
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Gan and Lee Pharmaceuticals, USA
- Target Recruit Count
- 285
- Registration Number
- NCT06737042
- Locations
- 🇺🇸
KUR Research Site Network, Columbia, Maryland, United States
🇺🇸ERG, Columbus, Ohio, United States
🇺🇸Ark Clinical Research, Long Beach, California, United States
Randomized Control Trial of Sleeve Gastrectomy with Tirzepatide in Maximizing Weight Loss
- Conditions
- Interventions
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Nicholas Skertich
- Target Recruit Count
- 42
- Registration Number
- NCT06734273
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
- Conditions
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Biomed Industries, Inc.
- Target Recruit Count
- 224
- Registration Number
- NCT06732245
- Locations
- 🇺🇸
Biomed Research Unit #90067-102, Los Angeles, California, United States
🇺🇸Biomed Research Unit # 92121-103, San Diego, California, United States
🇺🇸Biomed Research Unit # 94104-101, San Francisco, California, United States
Study of Tirzepatide for Recovery and Alcohol Use Management
- Conditions
- Interventions
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06727331
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Faulkner Hospital, Jamaica Plain, Massachusetts, United States
2024 Tirzepatide-Bariatric Surgery
- Conditions
- Interventions
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Marlene Starr
- Target Recruit Count
- 50
- Registration Number
- NCT06721507
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Study of ARO-INHBE in Adults With Obesity With and Without Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 78
- Registration Number
- NCT06700538
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 800
- Registration Number
- NCT06662383
- Locations
- 🇺🇸
Medical Advancement Centers of Arizona, Tempe, Arizona, United States
🇺🇸Mary & Dick Allen Diabetes Center, Newport Beach, California, United States
🇺🇸Artemis Institute for Clinical Research, San Diego, California, United States
Normal-weight Diabetes: Adipocyte-directed Therapy with Pioglitazone or Tirzepatide
- Conditions
- Interventions
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 104
- Registration Number
- NCT06657209
- Locations
- 🇺🇸
Stanford University, Clinical and Translational Research Unit (CTRU), Stanford, California, United States
Evaluation of Tirzepatide As an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
- Conditions
- Interventions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- T. John Winhusen, PhD
- Target Recruit Count
- 310
- Registration Number
- NCT06651177
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.